ArticleEndocrine connections2026
Circulating matrix GLA protein during puberty in healthy and central precocious puberty children.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMatrix GLA protein (MGP) is involved in the regulation of extracellular matrix mineralisation, including bone formation. The peripubertal years are critical for linear growth and acquisition of bone mass. Emerging evidence suggests that plasma concentrations of dephosphorylated undercarboxylated MGP (dp-ucMGP) may vary across pubertal stages, potentially reflecting its role in bone remodelling.
methodsThis study examines longitudinal changes in circulating plasma dp-ucMGP in two cohorts: 111 healthy Danish children (52% girls) aged 6-15 years from the Copenhagen Puberty Study and 15 female patients with central precocious puberty (CPP) before, during, and after GnRH analogue treatment.
resultsAge- and sex-specific reference curves were generated for healthy children and adolescents. Dp-ucMGP increased significantly with age and pubertal progression in both sexes, while it declined from mid-puberty exclusively in boys. In girls only, dp-ucMGP SD scores were associated with body weight and BMI. In girls with CPP, dp-ucMGP concentrations were lower compared with healthy puberty-matched girls (Tanner B2: P = 0.016, Tanner B3: P = 0.0072). Initiation of GnRH agonist in CPP resulted in a significant increase in dp-ucMGP (-1.21 SD (baseline) vs 0.30 SD (3 months), P = 0.0048) but plateaued after 12 months of treatment and further declined towards baseline at treatment cessation.
conclusionWe show that circulating dp-ucMGP concentrations increase with age and pubertal progression in healthy children, are lower in CPP patients, and are suppressed by GnRH agonist. Altogether, our findings support that circulating concentrations of dp-ucMGP reflect its role in bone remodelling and linear growth during puberty. PLAIN LANGUAGE SUMMARY: In this study, we show that matrix GLA protein (MGP), a regulator of bone formation, increases with pubertal progression in healthy children but is suppressed when puberty is pharmacologically blocked in girls with early puberty. Our findings provide new insights into the potential role of MGP in bone growth during puberty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.